National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia

Obinutuzumab (Gazyvaro®) in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.

Rapid Review

Commenced Completed Outcome
08/08/2014 11/09/2014 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
30/09/2014  02/04/2015 Reimbursement Not Recommended


December 2015

The HSE has approved reimbursement following confidential price negotiations.